Anti-D Rh0 immunoglobulin

Drug Profile

Anti-D Rh0 immunoglobulin

Alternative Names: Anti-D immunoglobulin; WinRho SDF

Latest Information Update: 16 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cangene Corporation
  • Developer Baxter Healthcare Corporation; Emergent BioSolutions
  • Class Immunoglobulins
  • Mechanism of Action Immunoglobulin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura; Immune thrombocytopenic purpura
  • No development reported Dengue; Thrombocytopenia

Most Recent Events

  • 01 Aug 2016 Emergent BioSolutions forms a spin-off Aptevo Therapeutics for its oncology and haematology products
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Thrombocytopenia in USA (IV, Injection)
  • 20 Mar 2015 No development reported - Phase-I/II for Dengue in Philippines (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top